Veralox Therapeutics logo Veralox Therapeutics
  • About Veralox
    • Meet the Team
  • Our Approach
  • Pipeline
    • Publications
  • Company News
  • Contact

Publications

  • Hematology
  • Diabetes
  • Other
Diabetes

12(S)-hydroxyeicosatetraenoic acid is significantly increased in diabetic kidney disease and associated with renal function decline

Xu et al. Diabetes Metab. Res. Rev. 2022;e3554 Read More
Diabetes

12-Lipoxygenase Products Reduce Insulin Secretion and β-Cell Viability in Human Islets

Ma et al. J. Clin. Endocrinol. Metab. 2010;95:887 Read More
Diabetes

Role of the 12-lipoxygenase pathway in diabetes pathogenesis and complications

Dobrian et al. Pharmacol. Ther. 2019;195:100 Read More
Diabetes

Elevated 12-hydroxyeicosatetraenoic acid (12-HETE) levels in serum of individuals with newly diagnosed Type 1 diabetes

Hennessy et al. Diabet. Med. 2017;34:292 Read More
Diabetes

Expression pattern of 12-lipoxygenase in human islets with type 1 diabetes and type 2 diabetes

Grzesik et al. J. Clin. Endocrinol. Metab. 100, E387 Read More
Diabetes

12-Lipoxygenase Inhibitor Improves Functions of Cytokine-Treated Human Islets and Type 2 Diabetic Islets

Ma et al. Clin. Endocrinl. Metab. 2017;102:2789 Read More
Diabetes

Proinflammatory signaling in islet β cells propagates invasion of pathogenic immune cells in autoimmune diabetes

Piñeros et al. Cell Reports 2022;39:13,111011 Read More
Veralox Therapeutics logo
Developing new therapies for life-threatening immuno-inflammatory diseases
Veralox Headquarters
4539 Metropolitan Ct
Frederick, MD 21704
301-360-3502
  • About Veralox
  • Our Approach
  • Pipeline
  • Team
  • Publications
  • Company News
  • Contact

Copyright 2023 | Website design by Wood Street, Inc.